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SUMMARY 
We have determined the molecular basis for hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
deficiency in a patient, J.H., with Lesch-Nyhan syndrome. Radioimmunoassay of lysates of erythrocytes or 
cultured B-lymphoblasts showed that this patient had no detectable HPRT enzyme activity or HPRT protein. 
HPRT-specific mRNA levels were normal by Northern analysis. 
We created a cDNA library from mRNA isolated from cultured lymphoblasts derived from this patient. 
Nucleotide sequencing of full-length HPRT cDNA clones revealed a single nucleotide (nt) substitution: a 
T-to-A transversion at nt 389. We have designated this variant HPRTNlidland. The predicted amino acid (aa) 
substitution in HPRTMidland is a valine to aspartic acid at aa 130. This substitution is within 2 aa of the amino 
acid substitution in a previously defined HPRT variant, HPRT,,, Arbor. Both mutations are within a highly 
conserved sequence in the putative Sphosphoribosyl-1-pyrophosphate-binding domain. The amino acid substi- 
tution in HPRTMidland causes a significant perturbation in the predicted secondary structure of this region. The 




ase (HPRT) is a cytoplasmic enzyme involved in the 
salvage of purine bases. HPRT catalyzes the for- 
mation of IMP and GMP from hypoxanthine and 
guanine, respectively. Partial deficiency of this en- 
zyme results in overproduction of uric acid leading 
to severe, precocious gout and nephrolithiasis 
(Kelley et al., 1967). Virtually complete deficiency of 
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HPRT causes Lesch-Nyhan syndrome consisting of 
hyperuricemia, hyperuricaciduria and devastating 
neurological dysfunction, the hallmarks of which are 
mental retardation, spasticity, choreoathetosis and 
compulsive self-mutilation (Lesch and Nyhan, 1964; 
Seegmiller et al., 1967). The importance of the study 
of HPRT goes beyond these human diseases. 
Because of selection systems for both the HPRT’ 
and HPRT- phenotypes, this protein and its gene 
have become important tools in genetic research 
(Szybalska and Szybalski, 1962; Rubin et al., 1971). 
Subjects with HPRT deficiency reveal a striking 
degree of phenotypic and genotypic variety (Yang 
et al., 1984; Wilson et al., 1986a; Gibbs and Caskey, 
1987). However, studies of the HPRT gene and 
mRNA from deficient subjects using Southern- and 
Northern-blot techniques are normal in most cases 
(Yang et al., 1984; Wilson et al., 1986a). Thus, more 
detailed analysis of HPRT gene sequences is neces- 
sary to understand themolecular bases for enzymatic 
abnormalities. 
Six mutant forms of HPRT from deficient subjects 
have been characterized previously at the molecular 
level. The amino acid substitutions in four mutant 
forms of HPRT were determined by amino acid se- 
quencing of aberrant peptides derived from highly 
purified erythrocyte HPRT from deficient subjects 
(Wilson and Kelley, 1983a; Wilson et al., 1983b, 
1984). This technique is limited to those HPRT- 
deficient subjects who express suflicient levels of 
HPRT protein for purification and amino acid se- 
quence determination. Furthermore, this technique 
is time consuming and does not necessarily reveal 
the underlying mutation. More recently, we have 
exploited the observation that approximately 80 % of 
HPRT deficient subjects have sufficient amounts of 
HPRT-specific mRNA for cDNA cloning in order to 
define the mutations in two other HPRT variants 
(Davidson et al., 1988; Fujimori et al., 1988). 
Previously identified mutations in HPRT are 
widely scattered throughout the primary structure. 
HPPTMidi,d, the mutant described in this study, is 
due to a single aa substitution located only two aa 
residues from a previously defined HPRT variant, 
HPRT,,, Arbor (Fujimori et al., 1988). Both muta- 
tions fall in the putative PRPP binding domain of 
HPRT (Argos et al., 1983). Additionally, the region 
in which these mutations are found is conserved 
among different species. 
EXPERIMENTAL AND DISCUSSION 
(a) Cell lines 
A patient (J.H.) with Lesch-Nyhan syndrome 
had undetectable levels of HPRT activity in both 
erythrocytes and cultured B-lymphoblasts (< 0.1 
mU/mg or < 0.7 y0 of control values) (Wilson et al., 
1986a). In addition, levels of HPRT protein were 
undetectable as measured by radioimmunoassay 
using polyclonal anti-human HPRT antiserum 
(< 1.5 ng CRM/mg or ~0.5% of control values) 
(Wilson et al., 1986a). We have designated HPRT 
from this patient, as HPRTmidland. 
HPRT,,, Arbor was originally described as an 
HPRT variant on the basis of enzymatic properties 
(Wilson et al., 1982a). The mutation responsible for 
HPRT,,, Arbor has been defined (Fujimori et al., 
1988). In contrast to J.H., this patient had partial 
HPRT deficiency with 10% of control levels of en- 
zyme activity, and 11 y0 of control values of CRM. 
J.H. lymphoblasts were maintained in RPM1 
medium with 5% fetal calf serum as described pre- 
viously (Wilson et al., 1982a). 
(b) cDNA cloning and isolation of recombinants 
Approximately 1 .O g (wet weight) of HPRThlidland 
B-lymphoblasts was used for extraction of total 
RNA using guanidium isothiocyanate (Chirgwin 
et al., 1979) followed by oligo(dT) chromatography 
to select for poly(A) + RNA (Aviv and Leder, 1972). 
Ohgo(dT), primed cDNAs were synthesized, 
using 5 to 20 fig of poly(A)+ RNA according to 
established procedures (Okayama and Berg, 1982; 
Gubler and Hoffman, 1983), and cloned in llgtl 1 
(Young and Davis, 1983). 
The resultant cDNA library was screened with an 
MyI-TuqI fragment of normal human HPR TcDNA 
which represents 5’-noncoding and coding se- 
quences (Brennand et al., 1983). This 160-bp frag- 
ment was labeled with [a-3ZP]dCTP using hexa- 
deoxynucleotide primers (Feinberg and Vogelstein, 
1984). 
Two HPRT-specific cDNA clones, pHPJH1 and 
pHJH7, were isolated. Recombinant phages were 
purified from 20 ml of phage lysate using standard 
techniques (Maniatis et al., 1982). The inserts were 
excised, separated from vector sequences and cloned 
Fig. 1. Sequencing strategy for HPRTlvIidland cDNA clones 
pHPJH1 and pHPJH7. Both pHPJH7, which extends to nt -72 
and pHPJH1, which extends to nt 12 were subcloned into the 
EcoRI site of M13mp18 or M13mp19 and sequenced with 
HPRT-specific oligodeoxynucleotide primers (arrows 1 through 
5) and the Ml3 universal primer (unlabeled arrows). The nucleo- 
tide sequences of the HPRT-specific oligodeoxynucleotide 
primers are listed in Table I. The ATG start codon, TAA stop 
codon and poly(A) tail are indicated. The Hind111 (H)-Bali (B) 
fragment (255 bp) was subcloned into Hind111 + SnzaI-cut 
M13mp18 and M13mp19 for determination of 3’-noncoding se- 
quences. These subclones were sequenced using the universal 
primer. The position of the mutation in pHPJH1 and pHPJH7 
is indicated by the asterisk. Both clones were sequenced entirely 
in both directions. Open bar, 5’ and 3’ noncoding sequences; 
solid bar, coding sequences; stippled bar, poly(A) tail. 
in M13mpl8 and M13mp19 for isolation of single- 
stranded phages (Messing, 1983). 
(c) Sequencing and recombinant analysis 
Sequences of pHPJH1 and pHPJH7 were deter- 
mined using the sequencing strategy described in 
Fig. 1. Single-stranded Ml3 recombinant phages 
were sequenced with [c+~~S]~ATP (Biggin et al., 
1983) using both the Ml3 universal primer and 
HPRT-specific primers. The sequences of the 
HPRT-specific primers are listed in Table I. Normal 
HPRT cDNA contains 590 nt of 3’-noncoding se- 
quence, 654 nt of coding sequence, and from 110 to 
170 nt of 5’-noncoding sequences (Jolly et al., 1982; 
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Pate1 et al., 1986). Clone pHPJH7 consisted of 590 
nt of 3’-noncoding sequence, 654 nt of coding se- 
quence, and 77 nt of 5’-noncoding sequence. 
pHPJH1 lacks 17 nt of coding sequence. Both clones 
were sequenced in their entirety in both directions 
(sense and antisense strands). 
Recombinant clones pHPJH1 and pHPJH7 dif- 
fered from normal human HPRT cDNA at a single 
nucleotide (Fig. 2): a T-to-A transversion at nt 389. 
This nucleotide substitution predicts a valine-to- 
aspartic acid substitution at aa 130 (Fig. 3). 
The mutation in HPRT~idland occurs in a region 
strongly conserved among human, rodent, and 
E. coli phosphoribosyltransferases (Table II). This 
was also the case in another HPRT variant with 
Lesch-Nyhan syndrome, HPRTFlint (Davidson 
et al., 1988). Such regions are probably important for 
maintenance of normal catalytic and kinetic prop- 
erties as well as structural integrity. The effect of the 
valine-to-aspartic acid change in HPRTMidland and 
the resultant disruption of this conserved sequence 
may induce secondary and/or tertiary structural 
changes which render the protein more unstable, 
accounting for the lack of detectable activity and 
protein in this mutant., 
The strongly conserved aa 129 through 137 have 
been implicated as part of the PRPP-binding domain 
(Argos et al., 1983). However, any catalytic conse- 
quence of the mutation in HPRTMidland cannot be 
determined because of insufficient residual protein 
and activity. HPRT,,, Ar,,or has an elevated K, for 
PRPP probably due to the isoleucine to methionine 
change at 132. As in HPRTMilidland, the diminished 
amount of CRM in HPRT,,, Arbor may result from 
disruption of secondary or tertiary structure leading 
to enhanced proteolysis. 
TABLE I 
HPRT-specific oligodeoxynucleotides: sequences and sites of priming 
Oligodeoxynucleotide Sequence (5’ to 3’) Priming site 
(nt) 
Strand” 
1 AGTGATGATGAACCAG 31- 47 
2 CACTGAATAGAAATAGT 25 l-267 
3 GATATAATTGACACTGG 403-419 - 
4 CCCCTGTTGACTGGTCA 337-321 + 
5 AGTCCTGTCCATAATTA 138-122 + 
a The DNA strand to which the primer anneals is represented as either sense ( + ) or antisense ( - ). 
Fig. 2. The nucleotide substitution in HPRTMidla,d. The sequencing gels for normal (left panel} and HPRTwidland (right panel) DNAs 
are shown from nt 385-393. Single-stranded phages intoning these sequences were sequenced using the ~deox~~cleotide chain 
termination method according to Biggin (1983) using JSPRT-specific primer 2 (Table I). One fourth of each sequencing reaction mix was 
electrophoresed on a 6% polyacrylamide gel containing 8 M urea at constant power (60 W). The gels were then transferred to Whatman 
paper, dried under vacuum, autoradiographed for 2 to 8 11, and developed. The sequence is shown between the panels with T (normal) 
transverted to an A (HPRTMidland). 
TABLE II 
The putative PRPP binding domain of various phosphoribosyltransferasesa 
Phospho~bosyl- 
transferase b 
Amino acids c Referenced 
129 130 131 132 133 134 135 136 137 





E. coli XGPRT 
Human APRT 
Mouse APRT 
E. cofi APRT 
E. coli OPRT 
E. coli GlnPRT 
asn val leu ile val glu asp ile ile 
asn asp leu ile val glu asp ile ile 
asn val leu met val glu asp ile ile 
asn val leu iie val glu asp ile ile 
asn val leu ile val glu asp ile iie 
- phe ile val ile asp asp leu val 
arg val val val val asp asp leu leu 
arg val val ile val asp asp leu leu 
lys val leu val val asp asp leu leu 
- Vd met leu val asp asp - val 
asn val leu leu vat asp asp ser ile 
A 
a This sequence is within a 35 residue stretch of aa predicted to be involved in PRPP binding, as based on secondary structure homology 
to E. coli GlnPRT (Argos et al., 1983). 
b XGPRT, xanthine-guanine phosphoribosyltransferase; APRT, adenine phosphoribosyltransferase; OPRT, orotate phosphoribosyl- 
transferase; GlnPRT, glutamine phosphoribosylp~ophosphate amidotransferase. 
c Residue numbers are based on the amino acid sequence of human HPRT (Wilson et al., 1982b). 
d A, Wilson et al. (1982b); B, Fujimori et al. (1988); C,D, Konecki et al. (1982); E, Pratt and Subramani (1983); F, Wilson et al. (1986b); 
G, Dush et al. (1985); H, Hershey and Taylor (1986); I, Poulsen et al. (1983); J, Tso et al. (1983). 







AAT AC TTG 
389 
AAT GmC -rrG 
Asn Val Leu 
130 
Fig. 3. The nucleotide and corresponding amino acid substi- 
tution in HPRTMidland. Nucleotides 385 through 393 and aa 129 
through 131 from both normal HPRT and HPRTMidland are 
shown. The nucleotide substitution is boxed. 
(d) Secondary structure predictions 
A computer-assisted analysis of predicted secon- 
dary structure perturbations caused by the amino 
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acid substitutions in HPRThlidland was performed 
(Chou and Fasman, 1978). Hydrophilicity moments 
were also calculated and overlaid on the secondary 
structure plots (Hopp and Woods, 1981). The Se- 
quence Analysis Software Package (Genetics Com- 
puter Group) for nucleic acid and protein structure 
analysis was used for calculation and plotting of 
predicted structures (Wolf et al., 1988). This soft- 
ware is available through the University of Wiscon- 
sin Biotechnology Center, Madison, WI 53705. 
Predicted secondary structures for normal HPRT 
and HPRTMidland are shown in Fig. 4. The predicted 
secondary structure for normal HPRT from aa 115 
to 145 consists of random coil/p-sheet/b-turn/& 
turn//I-sheet. Valine, which has the strongest propen- 
sity towards forming B-sheet structure is replaced by 
A 
Alpha helix fi 
Betasheet - 
Random coil - 
Hydrophilic&y > =1.3 0 
Hydrophobicity > ~1.3 0 
Fig. 4. Secondary structure predictions for normal HPRT and HPRTMidland. (Panel A) the predicted secondary structure of normal 
HPRT. The inset is an enlargement of the region contained within the box. (Panel B) The predicted secondary structure of HPRTMialand 
for the same region as the inset in panel A. The entire amino acid sequence for HPRTMidana and normal HPRT were analyzed using 
the PEPTIDESTRUCTURE and PLOTSTRUCTURE programs of the Genetic Computer Group nucleic acid and protein analysis 
package. The plot of the Chou-Fasman calculations includes regions of random coil, p-sheet, p-turn, and a-helix, as illustrated in the 
figure. The plot of HPRTMvlidland has two additional p-turns compared to that of normal HPRT. The hydrophobicity and hydrophilicity 
values (Hopp and Woods, 1981) are included in the secondary structure plots as diamonds and ovals, respectively. The size of the 
character is proportional to the magnitude of the attribute. 
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aspartic acid in HPRTlllidland. Aspartic acid has a 
strong propensity to disrupt P-sheet structure and to 
form /?-turn structure, especially in the context found 
in HPRTNIidland (Chou and Fasman, 1978). The 
predicted result of this mutation on the secondary 
structure is the replacement of the first region of 
B-sheet structure by two additional /%.trns beginning 
at or near aa 126 (Fig. 4). 
(e) Conclusions 
The genetic basis for enzyme deficiency in 
HPRTMidiand has been determined by cDNA clon- 
ing. A single nucleotide alteration was determined by 
sequencing two cDNA clones derived from a subject 
with Lesch-Nyhan syndrome. The mutation in 
HPRTMidiand is near the point mutation identified in 
HPRT,,, Arbor 3 a variant with partial HPRT activi- 
ty. The HPRThlidland mutation disrupts the putative 
PRPP binding domain which consists of a region of 
sequence of 9 aa strongly conserved among human, 
rodent and bacterial phosphoribosyltransferases. 
The structural alteration may impair protein stability 
leading to diminished amounts of CRM in cells de- 
rived from this subject. Altered secondary structure 
patterns are predicted for HPRTMidland, consistent 
with this hypothesis. The HPRTMidland mutation is 
167 nt away from a previously defined mutant, 
HPRTFii,t. 
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